CN105434400B - A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor - Google Patents
A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor Download PDFInfo
- Publication number
- CN105434400B CN105434400B CN201510981087.XA CN201510981087A CN105434400B CN 105434400 B CN105434400 B CN 105434400B CN 201510981087 A CN201510981087 A CN 201510981087A CN 105434400 B CN105434400 B CN 105434400B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- enteric
- pill
- layer coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
The invention discloses the preparation, spacer layer coating and enteric layer coatings of minimum enteric-coated micro-pill of a kind of proton pump inhibitor and preparation method thereof, including active pill core.The grain size of proton pump inhibitor enteric-coated micro-pill prepared by this method reaches 250~600 μm, can be fed by stomach tube；With good acid-resistant strength and stability, bioavilability is high；Simple, the contaminated risk of preparation process is small.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of preparation side of the minimum enteric-coated micro-pill of proton pump inhibitor
Method.
Background technology
Proton pump inhibitor is the state-of-the-art a kind of drug of current treatment peptic ulcer, is clinical application in recent ten years
Extensively, the best drug of curative effect, it is reached by efficient quickly gastric acid secretion inhibiting and removing helicobacter pylori quickly controls
More the purpose of ulcer.
Currently, proton pump inhibitor includes mainly that Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole and its institute are right
The products such as the salt (such as magnesium omeprazole) answered and single rotation isomers class (such as esomeprazole magnesium), product quantity is more, plants
Class is complete, with strong points, and therapeutic domain is wide.
Proton pump inhibitor is unstable under acid, heat and illumination condition, easily decomposes, need to improve its stabilization by preparation research
Property.Currently, the formulation products preparation process of most of proton pump inhibitor is complicated on the market, production cost is high and application range
It is narrow, therefore, it is badly in need of a kind of formulation products simple for process, cheap and that all groups can be served.
Invention content
It is 250~600 μm the object of the present invention is to provide a kind of grain size, the proton pump inhibitor pole of stomach tube feed can be passed through
The preparation method of small enteric-coated micro-pill；The acid-resistant strength and stability for improving proton pump inhibitor enteric-coated micro-pill, improve its biological utilisation
Degree；Easy preparation process reduces pollution risk.
The proton pump inhibitor enteric-coated micro-pill of the present invention contains：
(1) active pill core being made of proton pump inhibitor active ingredient and a variety of pharmaceutically acceptable excipients, is shown in Table 1.
1 active pill core prescription of table
Wherein proton pump inhibitor material fineness is 15 microns or less.
(2) separation layer, coating material are the Kollicoat IR (polyethylene of hydroxypropyl methylcellulose and BASF Corp. of Germany
Alcohol-polyethylene glycol (3:1) graft copolymer) it shares, it is shown in Table 2.
2 separation layer prescription of table
(3) enteric layer, coating material is that two kinds of polyacrylic resins share, by Eudragit L30D-55 and Eudragit
NE 30D compositions, are shown in Table 3.
3 enteric layer prescription of table
The preparation method of the proton pump inhibitor enteric-coated micro-pill of the present invention, includes the following steps：
(1) preparation of active pill core：Take micronizing proton pump inhibitor 100~120 parts by weight, hydroxypropyl methylcellulose 25~
30 parts by weight, 1~3 parts by weight of dimethicone, 2~4 parts by weight of disodium hydrogen phosphate, are gathered at 20~24 parts by weight of microcrystalline cellulose
80 3~6 parts by weight of sorb ester, 750~900 parts by weight of purified water, are configured to medicine layer coating solution；It is micro- with 80~100 parts by weight
Crystalline cellulose blank capsule core (grain size is 180~250 μm) is female ball, and spraying medicine technology using German Glatt fluid beds bottom prepares
The grain size of active pill core, the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：Take 10~15 parts by weight of hydroxypropyl methylcellulose, 6~9 parts by weight of Kollicoat IR, the third two
1.5~2 parts by weight of alcohol, 3~4 parts by weight of titanium dioxide, 95% ethyl alcohol, 300~400 parts by weight, are configured to spacer layer coating liquid；
Be female ball with medicine layer active pill core, spraying medicine technology using German Glatt fluid beds bottom carries out spacer layer coating, preparation every
The grain size of absciss layer base ball is 180~425 μm.
(3) enteric layer is coated：Take 200~240 parts by weight of Eudragit L30D-55, Eudragit NE 30D 50~
60 parts by weight, 7.5~9 parts by weight of triethyl citrate, 7.5~9 parts by weight of glycerin monostearate 40-55, polyoxyethylene sorbitan monoleate
3.75~4.5 parts by weight, 300~360 parts by weight of purified water, are configured to enteric layer coating solution；It is female ball with separation layer base ball, adopts
Medicine technology is sprayed with German Glatt fluid beds bottom and carries out enteric layer coating, and the grain size of the enteric-coated micro-pill of preparation is 250~600 μm.
Fluidized bed coating parameter is shown in Table 4.
4 fluidized bed coating parameter of table
The preparation process of the present invention once prepares completion, without discharging all using Germany's Glatt fluid beds, keeps away
Contaminated risk in material transfer process is exempted from；No intermediate control, it is easy to operate, human and material resources are saved, are relatively beneficial to
Workshop GMP is produced.
The grain size of proton pump inhibitor enteric-coated micro-pill prepared by the present invention is 250~600 μm, belongs to minimum pellet, can lead to
Stomach tube feed is crossed, especially suitable for the special population without autonomous feed ability.
Microcrystalline cellulose is added in the active pill core of the present invention, microcrystalline cellulose can enhance the roundness of ball, hardness
And toughness, so that active pill core is unlikely to broken in coating process.
Most of proton pump inhibitor is insoluble in water, and surface-active is added in the process for preparation of medicine layer coating solution of the present invention
Agent polyoxyethylene sorbitan monoleate is as solubilizer, wetting agent, but the stronger repellency of these proton pump inhibitors can make medicine layer coating solution
In contain a large amount of bubbles, therefore, be added dimethicone as antifoaming agent.
Separation layer influences the stability of proton pump inhibitor, and the Kollicoat IR of BASF Corp. of Germany are added in the present invention
(polyvinyl alcohol-polyethylene glycol (3:1) graft copolymer) it is shared as separation layer filmogen with hydroxypropyl methylcellulose,
The prodigious filming performances for enhancing hydroxypropyl methylcellulose of Kollicoat IR, improve the stability of pellet.
The mixture of preferred Eudragit L30D-55 and Eudragit NE 30D is as enteric-coating material in the present invention
Enteric-coated micro-pill is prepared, the acid-resistant strength of pellet is substantially increased under the premise of not influencing vitro release, capsule phase is ground with original
Compare and improves a lot.
Proton pump inhibitor capsulae enterosolubilis in the present invention for investigation uses gelatin by proton pump inhibitor enteric-coated micro-pill
Capsules are filling to be formed.
Specific implementation mode
The present invention is further explained with reference to embodiments, but is not intended to limit present disclosure.
Embodiment 1
By taking esomeprazole enteric capsules as an example
(1) preparation of active pill core：Take 120 grams of esomeprazole magnesium of micronizing, 30 grams of hydroxypropyl methylcellulose, microcrystalline cellulose
24 grams of element, 3 grams of dimethicone, 4 grams of disodium hydrogen phosphate, 6 grams of polyoxyethylene sorbitan monoleate, 900 grams of purified water, are configured to medicine layer packet
Clothing liquid；It is female ball with 100 grams of microcrystalline cellulose blank pellets (grain size is 180~250 μm), using German Glatt fluid beds bottom
It sprays medicine technology and prepares active pill core, the grain size of the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：Take 15 grams of hydroxypropyl methylcellulose, 9 grams of Kollicoat IR, 2 grams of propylene glycol, titanium dioxide 4
Gram, 400 grams of 95% ethyl alcohol, be configured to spacer layer coating liquid；It is female ball with medicine layer active pill core, is fluidized using German Glatt
Bed bottom sprays medicine technology and carries out spacer layer coating, and the grain size of the separation layer base ball of preparation is 180~425 μm.
(3) enteric layer is coated：Take 300 grams of Eudragit L30D-55,9 grams of triethyl citrate, glycerin monostearate
9 grams of 40-55,4.5 grams of polyoxyethylene sorbitan monoleate, 360 grams of purified water, are configured to enteric layer coating solution；It is female ball with separation layer base ball,
Medicine technology is sprayed using German Glatt fluid beds bottom and carries out enteric layer coating, the grain size of the enteric-coated micro-pill of preparation is 250~600 μ
m。
Fluidized bed coating parameter is with reference to table 4.
Embodiment 2
By taking esomeprazole enteric capsules as an example
(1) preparation of active pill core：Take 120 grams of esomeprazole magnesium of micronizing, 30 grams of hydroxypropyl methylcellulose, microcrystalline cellulose
24 grams of element, 3 grams of dimethicone, 4 grams of disodium hydrogen phosphate, 6 grams of polyoxyethylene sorbitan monoleate, 900 grams of purified water, are configured to medicine layer packet
Clothing liquid；It is female ball with 100 grams of microcrystalline cellulose blank pellets (grain size is 180~250 μm), using German Glatt fluid beds bottom
It sprays medicine technology and prepares active pill core, the grain size of the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：15 grams of hydroxypropyl methylcellulose, 2 grams of propylene glycol, 4 grams of titanium dioxide, 400 grams of 95% ethyl alcohol are taken,
It is configured to spacer layer coating liquid；It is female ball with medicine layer active pill core, spraying medicine technology using German Glatt fluid beds bottom carries out
The grain size of spacer layer coating, the separation layer base ball of preparation is 180~425 μm.
(3) enteric layer is coated：Take 300 grams of Eudragit L30D-55,9 grams of triethyl citrate, glycerin monostearate
9 grams of 40-55,4.5 grams of polyoxyethylene sorbitan monoleate, 360 grams of purified water, are configured to enteric layer coating solution；It is female ball with separation layer base ball,
Medicine technology is sprayed using German Glatt fluid beds bottom and carries out enteric layer coating, the grain size of the enteric-coated micro-pill of preparation is 250~600 μ
m。
Fluidized bed coating parameter is with reference to table 4.
Pellet (the lot number prepared according to embodiment 1：201106001) and according to embodiment 2 (being not added with Kollicoat IR)
Pellet (the lot number of preparation：201106002) study on the stability the results are shown in Table 5, table 6.
5 esomeprazole enteric capsules study on the stability result (201106001) of table
6 esomeprazole enteric capsules study on the stability result (201106002) of table
According to table 5,6 experimental result of table it is found that Kollicoat IR using the prodigious hydroxypropyl methylcellulose that enhances
Filming performance improves the stability of pellet.
Embodiment 3
By taking esomeprazole enteric capsules as an example
(1) preparation of active pill core：Take 100 grams of esomeprazole magnesium of micronizing, 25 grams of hydroxypropyl methylcellulose, microcrystalline cellulose
20 grams of element, 1 gram of dimethicone, 2 grams of disodium hydrogen phosphate, 3 grams of polyoxyethylene sorbitan monoleate, 750 grams of purified water, are configured to medicine layer packet
Clothing liquid；It is female ball with 80 grams of microcrystalline cellulose blank pellets (grain size is 180~250 μm), is sprayed using German Glatt fluid beds bottom
Medicine-feeding technology prepares active pill core, and the grain size of the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：Take 15 grams of hydroxypropyl methylcellulose, 9 grams of Kollicoat IR, 2 grams of propylene glycol, titanium dioxide 4
Gram, 400 grams of 95% ethyl alcohol, be configured to spacer layer coating liquid；It is female ball with medicine layer active pill core, is fluidized using German Glatt
Bed bottom sprays medicine technology and carries out spacer layer coating, and the grain size of the separation layer base ball of preparation is 180~425 μm.
(3) enteric layer is coated：Take 200 grams of Eudragit L30D-55,50 grams of Eudragit NE 30D, citric acid three
7.5 grams of ethyl ester, 7.5 grams of glycerin monostearate 40-55,3.75 grams of polyoxyethylene sorbitan monoleate, 300 grams of purified water, are configured to enteric
Layer coating solution；It is female ball with separation layer base ball, spraying medicine technology using German Glatt fluid beds bottom carries out enteric layer coating, system
The grain size of standby enteric-coated micro-pill is 250~600 μm.
Fluidized bed coating parameter is with reference to table 4.
Pellet (the lot number prepared according to embodiment 3：201107004) it grinds capsule contrasting detection with original and the results are shown in Table 7.
7 pellet acid-resistant strength of table is compared with vitro release
According to 7 experimental result of table it is found that the mixture of Eudragit L30D-55 and Eudragit NE 30D is as enteric
Coating material prepares enteric-coated micro-pill, and the acid-resistant strength of pellet is substantially increased under the premise of not influencing vitro release, with original
It grinds capsule and compares and improve a lot.
Embodiment 4
By taking Lansoprazole enteric pellet as an example
(1) preparation of active pill core：Take 120 grams of Lansoprazole of micronizing, 25 grams of hydroxypropyl methylcellulose, microcrystalline cellulose 20
Gram, 1 gram of dimethicone, 2 grams of disodium hydrogen phosphate, 3 grams of polyoxyethylene sorbitan monoleate, 900 grams of purified water, be configured to medicine layer coating solution；
It is female ball with 100 grams of microcrystalline cellulose blank pellets (grain size is 180~250 μm), medicine is sprayed using German Glatt fluid beds bottom
Technology prepares active pill core, and the grain size of the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：Take 10 grams of hydroxypropyl methylcellulose, 6 grams of Kollicoat IR, 1.5 grams of propylene glycol, titanium dioxide
3 grams of titanium, 300 grams of 95% ethyl alcohol, are configured to spacer layer coating liquid；It is female ball with medicine layer active pill core, is flowed using German Glatt
Change bed bottom and spray medicine technology progress spacer layer coating, the grain size of the separation layer base ball of preparation is 180~425 μm.
(3) enteric layer is coated：Take 200 grams of Eudragit L30D-55,50 grams of Eudragit NE 30D, citric acid three
7.5 grams of ethyl ester, 7.5 grams of glycerin monostearate 40-55,3.75 grams of polyoxyethylene sorbitan monoleate, 300 grams of purified water, are configured to enteric
Layer coating solution；It is female ball with separation layer base ball, spraying medicine technology using German Glatt fluid beds bottom carries out enteric layer coating, system
The grain size of standby enteric-coated micro-pill is 250~600 μm.
Fluidized bed coating parameter is with reference to table 4.
Embodiment 5
By taking Lansoprazole enteric pellet as an example
(1) preparation of active pill core：Take 120 grams of Lansoprazole of micronizing, 25 grams of hydroxypropyl methylcellulose, dimethicone 1
Gram, 2 grams of disodium hydrogen phosphate, 3 grams of polyoxyethylene sorbitan monoleate, 900 grams of purified water, be configured to medicine layer coating solution；With 100 grams of crystallite fibres
The plain blank capsule core (grain size is 180~250 μm) of dimension is female ball, and spraying medicine technology using German Glatt fluid beds bottom prepares activity
The grain size of capsule core, the active pill core of preparation is 180~425 μm.
(2) spacer layer coating：Take 10 grams of hydroxypropyl methylcellulose, 6 grams of Kollicoat IR, 1.5 grams of propylene glycol, titanium dioxide
3 grams of titanium, 300 grams of 95% ethyl alcohol, are configured to spacer layer coating liquid；It is female ball with medicine layer active pill core, is flowed using German Glatt
Change bed bottom and spray medicine technology progress spacer layer coating, the grain size of the separation layer base ball of preparation is 180~425 μm.
(3) enteric layer is coated：Take 200 grams of Eudragit L30D-55,50 grams of Eudragit NE 30D, citric acid three
7.5 grams of ethyl ester, 7.5 grams of glycerin monostearate 40-55,3.75 grams of polyoxyethylene sorbitan monoleate, 300 grams of purified water, are configured to enteric
Layer coating solution；It is female ball with separation layer base ball, spraying medicine technology using German Glatt fluid beds bottom carries out enteric layer coating, system
The grain size of standby enteric-coated micro-pill is 250~600 μm.
Fluidized bed coating parameter is with reference to table 4.
4 (lot number of embodiment：201108003) with 5 (lot number of embodiment：201108004) experimental phenomena and testing result are shown in
Table 8.
8 experimental phenomena of table and testing result comparison
According to experimental result it is found that the pellet that a small amount of microcrystalline cellulose is added generates under fluidized state without fragment.Therefore,
The application of microcrystalline cellulose makes pellet have good hardness and toughness, and pellet is non-breakable, is suitable for fluidized coating.
The experimental result of integrated embodiment 3~5 is it is found that proton pump inhibitor enteric prepared according to the methods of the invention is micro-
The acid-resistant strength and vitro release of ball all reach higher level.
The explanation of above example is only intended to facilitate the understanding of the method and its core concept of the invention.It should be pointed out that pair
For those skilled in the art, without departing from the principle of the present invention, the present invention can also be carried out
Some improvements and modifications, these improvement and modification are also fallen within the protection scope of the claims of the present invention.
Claims (4)
1. a kind of minimum enteric-coated micro-pill of proton pump inhibitor comprising the spacer layer coating of active pill core and active pill core, it is described
Active pill core include blank capsule core and medicine layer coating, wherein medicine layer coating solution includes following ingredient：It is micronized proton pump
100~120 parts by weight of inhibitor, 25~30 parts by weight of hydroxypropyl methylcellulose, 20~24 parts by weight of microcrystalline cellulose, dimethyl-silicon
Oily 1~3 parts by weight, 2~4 parts by weight of disodium hydrogen phosphate, 3~6 parts by weight of polysorbate, 750~900 parts by weight of purified water, with
80~100 parts by weight microcrystalline cellulose blank pellets are female ball, and wherein microcrystalline cellulose blank pellet grain size is 180~250 μm,
The active pill core grain size of preparation is 180~425 μm, which is characterized in that the spacer layer coating of active pill core includes following ingredient：Hydroxyl
Third methylcellulose, 10~15 parts by weight, 6~9 parts by weight of Kollicoat IR, 1.5~2 parts by weight of propylene glycol, titanium dioxide 3~
The grain size of 4 parts by weight, 95% ethyl alcohol, 300~400 parts by weight, the separation layer base ball of preparation is 180~425 μm.
2. the minimum enteric-coated micro-pill of a kind of proton pump inhibitor according to claim 1, which is characterized in that further include being used for institute
State the enteric layer coating of spacer layer coating, including following ingredient：200~240 parts by weight of Eudragit L30D-55,
50~60 parts by weight of Eudragit NE 30D, 7.5~9 parts by weight of triethyl citrate, glycerin monostearate 40-55 7.5
~9 parts by weight, 3.75~4.5 parts by weight of polyoxyethylene sorbitan monoleate, 300~360 parts by weight of purified water, the grain of the enteric-coated micro-pill of preparation
Diameter is 250~600 μm.
3. the minimum enteric-coated micro-pill of proton pump inhibitor as described in claim 1-2 any one, it is characterised in that：It prepares
The grain size of proton pump inhibitor enteric-coated micro-pill is 250~600 μm.
4. a kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor, its step are as follows：
(1) preparation of active pill core：Take 100~120 parts by weight of micronizing proton pump inhibitor, 25~30 weight of hydroxypropyl methylcellulose
Measure part, 20~24 parts by weight of microcrystalline cellulose, 1~3 parts by weight of dimethicone, 2~4 parts by weight of disodium hydrogen phosphate, poly- sorb
80 3~6 parts by weight of ester, 750~900 parts by weight of purified water, are configured to medicine layer coating solution；It is fine with 80~100 parts by weight crystallites
The plain blank capsule core of dimension is female ball, and wherein microcrystalline cellulose blank pellet grain size is 180~250 μm, using German Glatt fluid beds
Bottom sprays medicine technology and prepares active pill core, and the grain size of the active pill core of preparation is 180~425 μm；
(2) spacer layer coating：Take 10~15 parts by weight of hydroxypropyl methylcellulose, 6~9 parts by weight of Kollicoat IR, propylene glycol
1.5~2 parts by weight, 3~4 parts by weight of titanium dioxide, 95% ethyl alcohol, 300~400 parts by weight, are configured to spacer layer coating liquid；With
Medicine layer active pill core is female ball, and spraying medicine technology using German Glatt fluid beds bottom carries out spacer layer coating, the isolation of preparation
The grain size of layer base ball is 180~425 μm；
(3) enteric layer is coated：Take 200~240 parts by weight of Eudragit L30D-55,50~60 weights of Eudragit NE 30D
Measure part, 7.5~9 parts by weight of triethyl citrate, 7.5~9 parts by weight of glycerin monostearate 40-55, polyoxyethylene sorbitan monoleate
3.75~4.5 parts by weight, 300~360 parts by weight of purified water, are configured to enteric layer coating solution；It is female ball with separation layer base ball, adopts
Medicine technology is sprayed with German Glatt fluid beds bottom and carries out enteric layer coating, and the grain size of the enteric-coated micro-pill of preparation is 250~600 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981087.XA CN105434400B (en) | 2015-12-24 | 2015-12-24 | A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510981087.XA CN105434400B (en) | 2015-12-24 | 2015-12-24 | A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105434400A CN105434400A (en) | 2016-03-30 |
| CN105434400B true CN105434400B (en) | 2018-09-21 |
Family
ID=55545337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510981087.XA Active CN105434400B (en) | 2015-12-24 | 2015-12-24 | A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434400B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531338B (en) * | 2022-10-28 | 2024-04-02 | 成都恒瑞制药有限公司 | Febuxostat tablet and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596165A (en) * | 2008-06-04 | 2009-12-09 | 永信药品工业(昆山)有限公司 | Enteric coated mini-pill of pantoprazole sodium |
| CN102008449A (en) * | 2010-11-15 | 2011-04-13 | 扬子江药业集团有限公司 | Lansoprazole enteric pellet and preparation method thereof |
| CN102240273A (en) * | 2010-05-13 | 2011-11-16 | 上海安圣医药科技有限公司 | Preparation method of lansoprazole enteric capsules |
| CN102652734A (en) * | 2011-03-03 | 2012-09-05 | 中国科学院上海药物研究所 | Rabeprazole sodium enterosoluble micro-particles and preparation method thereof |
| CN105125517A (en) * | 2015-07-16 | 2015-12-09 | 广东彼迪药业有限公司 | Esomeprazole magnesium enteric pellet capsule and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2313088A2 (en) * | 2008-08-11 | 2011-04-27 | Mepha GmbH | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
-
2015
- 2015-12-24 CN CN201510981087.XA patent/CN105434400B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596165A (en) * | 2008-06-04 | 2009-12-09 | 永信药品工业(昆山)有限公司 | Enteric coated mini-pill of pantoprazole sodium |
| CN102240273A (en) * | 2010-05-13 | 2011-11-16 | 上海安圣医药科技有限公司 | Preparation method of lansoprazole enteric capsules |
| CN102008449A (en) * | 2010-11-15 | 2011-04-13 | 扬子江药业集团有限公司 | Lansoprazole enteric pellet and preparation method thereof |
| CN102652734A (en) * | 2011-03-03 | 2012-09-05 | 中国科学院上海药物研究所 | Rabeprazole sodium enterosoluble micro-particles and preparation method thereof |
| CN105125517A (en) * | 2015-07-16 | 2015-12-09 | 广东彼迪药业有限公司 | Esomeprazole magnesium enteric pellet capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105434400A (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1108425B1 (en) | New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles | |
| ES2236943T3 (en) | SOLID DISSOLUTION PEARLS. | |
| ES2716550T3 (en) | Gastro-resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid | |
| CA2895529C (en) | Supersaturated stabilized nanoparticles for poorly soluble drugs | |
| JP5378465B2 (en) | Granule production method | |
| WO2007018943A2 (en) | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | |
| CZ18599A3 (en) | Formulation with multiple unit of tramadol | |
| CA2318008A1 (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
| CN102100671B (en) | Method for preparing esomeprazole enteric capsules | |
| RU2013141534A (en) | L-MENTHOL COMPOSITIONS CONSISTING OF A SET OF PARTICLES AND RELATED METHODS | |
| CN104414978A (en) | Enteric-coated micropellet containing esomeprazole magnesium | |
| CN105125517A (en) | Esomeprazole magnesium enteric pellet capsule and preparation method thereof | |
| CN104586809A (en) | Esomeprazole magnesium enteric pill coated tablet and preparation method thereof | |
| CN105434400B (en) | A kind of preparation method of the minimum enteric-coated micro-pill of proton pump inhibitor | |
| CN102631327B (en) | Enteric coated omeprazole pellet and preparation method thereof | |
| CN102641285A (en) | Compound omeprazole capsule and preparation method thereof | |
| CN102641286A (en) | Compound omeprazole dry suspension and preparation method thereof | |
| CN104940170A (en) | Esomeprazole magnesium enteric capsule and preparation method thereof | |
| US10881615B2 (en) | Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof | |
| EP1594479A1 (en) | Stable oral benzimidazole compositions and processes for their preparation | |
| CN103301074B (en) | Diammonium glycyrrhizinate enteric-coated pellet as well as preparation method and preparation thereof | |
| EP1108431B1 (en) | Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam | |
| CN103505421B (en) | A kind of enteric coated pellets formulation of duloxetine hydrochloride | |
| KR20120034264A (en) | Oral solid preparation composition containing silymarin using membrane emulsification technique, and its production method | |
| CN105726509A (en) | Pantozol medicine capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of proton pump inhibitor very small intestine soluble pellets Effective date of registration: 20220630 Granted publication date: 20180921 Pledgee: Shandong Shouguang Rural Commercial Bank Co.,Ltd. Pledgor: SHOUGUANG FUKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980009599 |